

Katherine M Hannan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9185802/publications.pdf>

Version: 2024-02-01

59
papers

3,654
citations

136740

32
h-index

143772

57
g-index

64
all docs

64
docs citations

64
times ranked

5400
citing authors

#	ARTICLE	IF	CITATIONS
1	mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBF. <i>Molecular and Cellular Biology</i> , 2003, 23, 8862-8877.	1.1	390
2	The nucleolus: an emerging target for cancer therapy. <i>Trends in Molecular Medicine</i> , 2013, 19, 643-654.	3.5	205
3	Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. <i>Growth Factors</i> , 2007, 25, 209-226.	0.5	204
4	Targeting the nucleolus for cancer intervention. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 802-816.	1.8	198
5	UBF levels determine the number of active ribosomal RNA genes in mammals. <i>Journal of Cell Biology</i> , 2008, 183, 1259-1274.	2.3	171
6	MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. <i>EMBO Journal</i> , 2004, 23, 3325-3335.	3.5	166
7	AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer. <i>Science Signaling</i> , 2011, 4, ra56.	1.6	126
8	Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age. <i>Cells</i> , 2020, 9, 266.	1.8	121
9	The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2015, 1849, 821-829.	0.9	105
10	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. <i>Cancer Discovery</i> , 2016, 6, 59-70.	7.7	105
11	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. <i>Oncotarget</i> , 2016, 7, 49800-49818.	0.8	93
12	Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. <i>Blood</i> , 2008, 112, 2305-2317.	0.6	92
13	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. <i>Nature Communications</i> , 2020, 11, 2641.	5.8	90
14	Direct Identification of Tyrosine 474 as a Regulatory Phosphorylation Site for the Akt Protein Kinase. <i>Journal of Biological Chemistry</i> , 2002, 277, 38021-38028.	1.6	88
15	A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition. <i>Cancer Research</i> , 2006, 66, 11718-11725.	0.4	85
16	RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest. <i>Oncogene</i> , 2000, 19, 3487-3497.	2.6	81
17	Regulation of rDNA transcription in response to growth factors, nutrients and energy. <i>Gene</i> , 2015, 556, 27-34.	1.0	79
18	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. <i>Blood</i> , 2017, 129, 2882-2895.	0.6	74

#	ARTICLE	IF	CITATIONS
19	Autophagy Induction Is a Tor- and Tp53-Independent Cell Survival Response in a Zebrafish Model of Disrupted Ribosome Biogenesis. <i>PLoS Genetics</i> , 2013, 9, e1003279.	1.5	73
20	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. <i>European Journal of Cancer</i> , 2013, 49, 3936-3944.	1.3	72
21	The long noncoding RNA lincNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. <i>Nature Communications</i> , 2019, 10, 5026.	5.8	67
22	Diabetes-Induced Vascular Hypertrophy Is Accompanied by Activation of Na ⁺ -H Exchange and Prevented by Na ⁺ -H Exchange Inhibition. <i>Circulation Research</i> , 2000, 87, 1133-1140.	2.0	63
23	Regulation of ribosomal DNA transcription by insulin. <i>American Journal of Physiology - Cell Physiology</i> , 1998, 275, C130-C138.	2.1	61
24	Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. <i>Blood</i> , 2013, 121, 2964-2974.	0.6	59
25	The mTORC1 Inhibitor Everolimus Prevents and Treats E1/4-Myc Lymphoma by Restoring Oncogene-Induced Senescence. <i>Cancer Discovery</i> , 2013, 3, 82-95.	7.7	58
26	New Roles for the Nucleolus in Health and Disease. <i>BioEssays</i> , 2018, 40, e1700233.	1.2	53
27	Activation of S6K1 (p70 ribosomal protein S6 kinase 1) requires an initial calcium-dependent priming event involving formation of a high-molecular-mass signalling complex. <i>Biochemical Journal</i> , 2003, 370, 469-477.	1.7	52
28	Phosphorylation regulates copper-responsive trafficking of the Menkes copper transporting P-type ATPase. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 2403-2412.	1.2	52
29	A functional genetic screen defines the AKT-induced senescence signaling network. <i>Cell Death and Differentiation</i> , 2020, 27, 725-741.	5.0	40
30	Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. <i>Journal of Diabetes and Its Complications</i> , 2001, 15, 120-127.	1.2	39
31	Troglitazone Stimulates Repair of the Endothelium and Inhibits Neointimal Formation in Denuded Rat Aorta. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 762-768.	1.1	36
32	PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth. <i>BMC Molecular and Cell Biology</i> , 2020, 21, 24.	1.0	36
33	Signaling to the ribosome in cancer – It is more than just mTORC1. <i>IUBMB Life</i> , 2011, 63, 79-85.	1.5	35
34	Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005432.	1.3	34
35	Determination of the Exact Molecular Requirements for Type 1 Angiotensin Receptor Epidermal Growth Factor Receptor Transactivation and Cardiomyocyte Hypertrophy. <i>Hypertension</i> , 2011, 57, 973-980.	1.3	27
36	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2021, 124, 616-627.	2.9	26

#	ARTICLE	IF	CITATIONS
37	The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 210.	1.8	20
38	Mechanisms regulating the vascular smooth muscle Na/H exchanger (NHE-1) in diabetes. <i>Biochemistry and Cell Biology</i> , 1998, 76, 751-759.	0.9	19
39	<sc>AKT</sc> signalling is required for ribosomal <sc>RNA</sc> synthesis and progression of <sc>E</sc>1/4<sc>Myc </i><sc>B</sc> cell lymphoma <i>in vivo</i>. <i>FEBS Journal</i> , 2013, 280, 5307-5316. ^{2,2}		19
40	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. <i>Oncogene</i> , 2019, 38, 3824-3842.	2.6	17
41	Reprogrammed <sc>mRNA</sc> translation drives resistance to therapeutic targeting of ribosome biogenesis. <i>EMBO Journal</i> , 2020, 39, e105111.	3.5	17
42	Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents. <i>Materials Horizons</i> , 2020, 7, 1996-2010.	6.4	17
43	A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth. <i>Cellular Signalling</i> , 2011, 23, 1338-1347.	1.7	16
44	Relative Expression Levels Rather Than Specific Activity Plays the Major Role in Determining <i>In Vivo</i> AKT Isoform Substrate Specificity. <i>Enzyme Research</i> , 2011, 2011, 1-18.	1.8	16
45	Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70s6k/p85s6k: implications for the analysis of S6K signalling. <i>FEBS Letters</i> , 2002, 519, 135-140.	1.3	15
46	S6 Kinase is essential for MYC-dependent rDNA transcription in <i>Drosophila</i> . <i>Cellular Signalling</i> , 2015, 27, 2045-2053.	1.7	15
47	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 568.	1.8	15
48	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression. <i>Cancer Research</i> , 2020, 80, 3706-3718.	0.4	15
49	Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription. <i>Gene</i> , 2017, 612, 36-48.	1.0	14
50	The Ribosomal Gene Loci—The Power behind the Throne. <i>Genes</i> , 2021, 12, 763.	1.0	14
51	Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. <i>World Journal of Gastroenterology</i> , 2017, 23, 2276.	1.4	13
52	Functional microRNA targetome undergoes degeneration-induced shift in the retina. <i>Molecular Neurodegeneration</i> , 2021, 16, 60.	4.4	10
53	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. <i>Oncotarget</i> , 2016, 7, 48887-48904.	0.8	8
54	Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence. <i>Assay and Drug Development Technologies</i> , 2016, 14, 416-428.	0.6	8

#	ARTICLE	IF	CITATIONS
55	High-Content Imaging Approaches to Quantitate Stress-Induced Changes in Nucleolar Morphology. Assay and Drug Development Technologies, 2018, 16, 320-332.	0.6	7
56	Too much or too little. Cell Cycle, 2012, 11, 3147-3148.	1.3	4
57	The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma. Investigational New Drugs, 2022, 40, 529-536.	1.2	3
58	MODULATION OF RNA POLYMERASE I TRANSCRIPTION IN NORMAL AND MALIGNANT HAEMATOPOIESIS. Experimental Hematology, 2019, 76, S65-S66.	0.2	0
59	The Synthesis and Biological Evaluation of Some C-9 and C-10 Substituted Derivatives of the RNA Polymerase I Transcription Inhibitor CX-5461. Australian Journal of Chemistry, 2021, 74, 540.	0.5	0